Business Context and Reporting Period
This Form 8-K was filed by Galectin Therapeutics Inc. on September 16, 2015. The report serves as a current disclosure pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. The primary purpose of this filing is to disclose a press release issued on the same date under Item 7.01 (Regulation FD Disclosure).
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing to announce a press release and does not contain audited financial statements or detailed financial data.
Material Changes
No material changes to financial performance or operations are detailed within the text of this specific filing. The document references an attached press release (Exhibit 99.1) for the substantive information but does not summarize the content of that release.
Guidance, Outlook, and Risks
The filing explicitly states that the information furnished under Item 7.01 shall not be deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section. It further notes that the information shall not be deemed incorporated by reference in any other filing unless expressly set forth by specific reference. No specific guidance, outlook, or risk factors are enumerated in the body of this report.
Key Facts for Investor Verification
- Verify the content of the attached Press Release (Exhibit 99.1) for the actual material non-public information disclosed.
- Note that the disclosure in this 8-K is not incorporated by reference into other SEC filings unless specifically cited.
- Confirm the company's status as a Nevada corporation with its principal executive office in Norcross, GA.
- Identify Jack W. Callicutt as the Chief Financial Officer who authorized the filing.